In vitro activity of tigecycline against Brucella spp.

Trakya Universitesi Tip Fakultesi Dergisi

Volumn 26, Issue 3, 2009, Pages 261-263

  Altun, Belgin ^a   Hasçelik, Gülşen ^a   Gür, Deniz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Brucella spp.; Tigecycline

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BRUCELLA; BRUCELLOSIS; CONTROLLED STUDY; EPSILOMETER TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 70350065926     PISSN: 13013149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Akova M, Gür D, Livermore DM, Kocagöz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999;43:1298-1300
2. Elfaki MG, Uz-Zaman T, Al-Hokail AA, Nakeeb SM. Detection of Brucella DNA in sera from patients with brucellosis by polymerase chain reaction. Diagn Microbiol Infect Dis 2005;53:1-7. (Pubitemid 41337991)
3. Gür D, Kocagöz S, Akova M, Unal S. Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999;43:2337. (Pubitemid 29421232)
4. Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991;35:1925-1927
5. Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 2007;39:432-434 (Pubitemid 46705755)
6. Clinical and Laboratory Standards Institute. 2007. M100-S17. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993;37:1831-1834 (Pubitemid 23265537)
8. García-Rodríguez JA, Muñoz Bellido JL, Fresnadillo MJ, Trujillano I. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob Agents Chemother 1993;37:911-913
9. García-Rodríguez JA, García Sánchez JE, Trujillano I, García Sánchez E, García García MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995;39:1194-1195
10. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003;35:337-338 (Pubitemid 36889331)
11. Turan H, Arslan H, Azap OK, Serefhanoǧlu K, Uncu H. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp. Int J Antimicrob Agents 2007;30:186-187